Oklahoma Cancer Specialists and Research Institute Selects BioCareSD and AllyGPO as Primary Drug Distributor and GPO Partner

TULSA, Okla., June 18, 2025 /PRNewswire/ -- Oklahoma Cancer Specialists and Research Institute (OCSRI), a leading independent community oncology practice, has officially selected BioCareSD and AllyGPO as its primary specialty drug distributor and group purchasing organization (GPO). This strategic partnership marks a milestone for both organizations and underscores the increasing demand for innovation, flexibility, and independence in oncology care.

By choosing BioCareSD and AllyGPO, OCSRI reinforces its commitment to maintaining complete independence while accessing cutting-edge drug management tools, competitive supply contracts, and personalized support. The alignment is rooted in shared values of transparency, teamwork, and a steadfast belief in empowering community oncology.

"Being fiercely independent has enabled OCSRI to provide the uncompromising care and quality that we're known for," said Dr. Daron Street, President at OCSRI. "BioCareSD and AllyGPO don't just talk about building trust, they walk the walk. Their collaboration, innovation, and actions demonstrated that they're in business to support the vitality of community oncology practices and preserve our independence."

OCSRI cited several key reasons for selecting BioCareSD and AllyGPO, including:

• A commitment to transparency in pricing and business operations
• Reduction in administrative burden through streamlined GPO contract management
• High-touch customer service and advanced drug management technology
•  Advocacy and continued investment in community oncology

The partnership represents a significant step forward for BioCareSD and AllyGPO as new entrants in a highly consolidated industry. Their selection by a nationally respected institution like OCSRI serves as proof that greater optionality in specialty wholesalers and GPOs is not only desired—it is essential.

"Having the endorsement of OCSRI—with its legacy of delivering groundbreaking, community-based oncology care and savvy practice management—reinforces why BioCareSD invested in a unique oncology platform," said James Frary, CEO of BioCareSD. "We're thrilled to support OCSRI and provide a differentiated experience rooted in choice, service, and innovation."

"OCSRI is an inspiration. They've challenged the status quo and faced strong industry headwinds to build and grow a practice that today has 90,000 visits per year from cancer patients across Oklahoma and surrounding states," said Brian Ansay, CEO of AllyGPO. "We are proud to support OCSRI and all of our community oncology members—advocating for their unique value with our pharmaceutical partners and equipping them with expertise and technology to help optimize drug utilization and economics so they can continue to care for patients their way."

This partnership is more than a new agreement—it is a powerful statement about what's possible when mission-aligned organizations unite to support the future of independent, patient-centered cancer care.

About OCSRI
OCSRI (Oklahoma Cancer Specialists and Research Institute) is a leader and patient-centric oncology institute providing renowned multidisciplinary care empowered by progressive clinical research. As a physician-owned network rooted in Tulsa, Oklahoma, OCSRI is driven by compassionate relationships and a commitment to excellence. With a team of nationally accredited specialists, they provide personalized treatment, transparent counsel, and advanced technology to deliver the most effective care possible. Visit www.ocsri.org to learn more.

About BioCareSD
BioCareSD, a BioCare company, is a national specialty distributor with more than 40 years of experience delivering life-saving specialty therapies. With a commitment to redefining specialty distribution, BioCareSD focuses on trust, transparency, and operational excellence. The company provides a high-touch, personalized service through a dedicated support team and 24/7/365 customer care. Its expanding portfolio and distribution model support its partners in their mission to save lives. For more information, visit www.biocaresd.com.

About AllyGPO
AllyGPO combines new-school technology with old-school concierge service to help community practices maintain their independence. AllyOncology GPO is dedicated to the unique needs of the oncology clinic class of trade. AllyIQ is a comprehensive technology platform for GPO administration, business intelligence, and inventory management with the first, fully smart oncology drug cabinet. Together with cutting-edge drug management, timely, accurate analytics, and expert guidance, AllyGPO helps practices improve efficiency, enhance financial performance, and keep community oncology care viable and growing. Learn more at www.AllyGPO.com/oncology.

For press inquiries, please contact:
Dara Shulman
396787@email4pr.com
415-871-5203

View original content to download multimedia:https://www.prnewswire.com/news-releases/oklahoma-cancer-specialists-and-research-institute-selects-biocaresd-and-allygpo-as-primary-drug-distributor-and-gpo-partner-302485216.html

SOURCE AllyGPO | BioCareSD